About SOTIO
SOTIO is a company based in Prague (Czechia) founded in 2010 was acquired by PPF Group in June 2012. It operates as a Professional Services. SOTIO has completed 1 acquisition, including CytunePharma. SOTIO offers products and services including SOT106, SOT109, and Nanrilkefusp alfa. SOTIO operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Prague, Czechia
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sotio Biotech A.S.
-
Annual Revenue
$8.12 K (USD)0as on Dec 31, 2021
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
PPF Group
(Jun 01, 2012)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SOTIO
SOTIO offers a comprehensive portfolio of products and services, including SOT106, SOT109, and Nanrilkefusp alfa.
SOT106 is developed as an ADC targeting LRRC15.
SOT109 is designed to target cadherin-17 in cancers.
Nanrilkefusp alfa is developed for targeted immune activation.
People of SOTIO
Unlock access to complete
Unlock access to complete
Funding Insights of SOTIO
Detailed funding history for SOTIO
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in SOTIO
SOTIO has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include PPF Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PPF Group is engaged in international investment across diverse sectors.
|
Locked | Locked | Locked |
Investor details for SOTIO
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SOTIO
SOTIO has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include CytunePharma.
Investment portfolio details for SOTIO
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Immunostimulatory agents and conjugated monoclonal antibodies for cancer are developed.
|
Locked | Locked | 2007 | Locked |
Complete acquisition details for SOTIO
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - SOTIO
Detailed financials for SOTIO
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sotio Comparisons
Peer comparison for SOTIO
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SOTIO
SOTIO operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of SOTIO
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sotio
Complete news archive for SOTIO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SOTIO
SOTIO was founded in 2010.
SOTIO is headquartered in Prague, Czechia.
Radek Spisek is the current CEO of SOTIO.
Annual revenue of SOTIO is $8.12K as on Dec 31, 2021.
SOTIO Biotech is engaged in the development of next-generation immunotherapies for cancer treatment. The companys pipeline includes internally developed and in-licensed candidates targeting various solid tumor types. Solutions such as antibody-drug conjugates and immunocytokines are being advanced through clinical development to provide safer and more effective treatments. The focus is placed on translating scientific innovation into patient benefits within the oncology sector.
SOTIO's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
SOTIO offers SOT106, SOT109, and Nanrilkefusp alfa.
SOTIO has made 1 acquisition, including CytunePharma.
SOTIO has 1 investor. Key investors include PPF Group.